Monoamine Oxidase Inhibitors (MAOIs) Depletions: What Antidepressant Medications Deplete

Monoamine Oxidase Inhibitors are among the oldest antidepressants in medicine, discovered in the 1950s when tuberculosis patients taking iproniazid unexpectedly experienced mood elevation. These medications work by irreversibly blocking monoamine oxidase enzymes (MAO-A and MAO-B) that normally break down serotonin, dopamine, and norepinephrine in the brain, allowing these neurotransmitters to accumulate in the synapse. Four MAOIs remain in clinical use: [phenelzine](/medications), [tranylcypromine](/medications), [isocarboxazid](/medications), and [selegiline transdermal](/medications). Despite their effectiveness — particularly for atypical depression and treatment-resistant cases — MAOI prescriptions have declined to approximately 1 million annually in the United States, driven largely by strict dietary tyramine restrictions and the availability of newer alternatives. CTD documents 11 chemical-gene interactions for phenelzine and 29 for tranylcypromine, reflecting their distinct pharmacological profiles despite sharing the same therapeutic target.

The critical nutrient depletion with MAOIs involves vitamin B6, but the mechanism splits sharply between drug subtypes. Phenelzine and isocarboxazid are hydrazine MAOIs — their chemical structure includes a hydrazine group that directly binds to pyridoxal-5-phosphate (P5P), the biologically active form of B6, creating stable hydrazine-PLP complexes that permanently inactivate the vitamin. This direct chemical trapping is unique among psychiatric medications and explains why phenelzine users develop B6 deficiency far more readily than patients on other antidepressants. Tranylcypromine, a non-hydrazine MAOI, does not share this binding mechanism and carries minimal B6 depletion risk. Transdermal selegiline at its lowest dose (6 mg/24h) bypasses gastrointestinal MAO inhibition entirely, further reducing metabolic impacts. CTD reports 800 disease associations for phenelzine and 733 for tranylcypromine, highlighting how these structurally different drugs produce overlapping therapeutic effects but divergent nutrient consequences.

B6 depletion from hydrazine MAOIs creates a particularly insidious clinical problem because B6 is the essential cofactor for the very neurotransmitter pathways these drugs aim to boost. Pyridoxal-5-phosphate is required by aromatic L-amino acid decarboxylase — the enzyme converting L-DOPA to dopamine and 5-HTP to serotonin. When phenelzine traps P5P, it simultaneously increases neurotransmitter survival (by blocking breakdown) and reduces neurotransmitter production (by depleting the synthesis cofactor). The result: patients may initially improve, then plateau or regress as B6 stores deplete over weeks to months. Peripheral neuropathy — tingling and numbness in hands and feet — develops in roughly 15% of phenelzine users according to FAERS data, and is frequently misattributed to the underlying psychiatric condition rather than being recognized as a correctable vitamin deficiency. Women of reproductive age face additional risks, as B6 deficiency exacerbates premenstrual symptoms and elevates homocysteine levels. Elderly patients, who comprise approximately 35% of MAOI users, absorb B6 less efficiently and deplete faster.

Managing MAOI-induced B6 depletion requires the active P5P form rather than standard pyridoxine, because phenelzine binds specifically to the activated vitamin. Supplementation with P5P at 50-100 mg daily (higher than the 25-50 mg typically recommended for other drug classes) addresses the direct binding mechanism. Plasma P5P testing provides the most accurate assessment of functional B6 status, with optimal levels between 20-50 ng/mL — a narrower and higher range than the conventional 5-50 ng/mL cutoff. The [vitamin panel](/biomarkers/vitamin-panel) should include P5P alongside other B-vitamins. Neurological examinations every 3-6 months help detect early neuropathy signs in phenelzine and isocarboxazid users. Critically, patients on any MAOI must avoid serotonergic supplements (5-HTP, L-tryptophan, St. John's Wort, SAMe) due to serotonin syndrome risk — a potentially fatal interaction. A 2-week washout period (5 weeks for fluoxetine) is required when switching between MAOIs and SSRIs.